Effects of Miglitol on Endothelial Vascular Reactivity in Type 2 Diabetic Patients with Coronary Heart Disease

Effects of Miglitol on Endothelial Vascular Reactivity in Type 2 Diabetic Patients with Coronary Heart Disease - J-MACH

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002264

Enrollment

Registered

2009-07-30

Start date

2007-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetic patients with coronary heart disease

Interventions

Miglitol 50mg Voglibose 0.3mg Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients with coronary heart disease. HbA1c <= 8% and casual blood glucose >= 200mg/dL.

Exclusion criteria

Exclusion criteria: Type 1 diabetes. Patients receiving insulin therapy. Patients with one of the following clinical conditions: severe liver dysfunction, severe renal dysfunction, congestive heart failure, acute coronary syndrome within 3 months, and other severe concomitant diseases. Patients who are judged inappropriate for entry into this study by the investigator.

Design outcomes

Primary

Measure	Time frame
Endothelial function evaluated by plethysmography	—

Secondary

Measure	Time frame
blood glucose, serum insulin, lipid, oxidative stress marker, inflammatory marker, incretin	—

Countries

Japan

Contacts

Public ContactMakoto Hiki

Juntendo University School of Medicine Department of Cardiovascular Medicine

m-hiki@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026